Canada Albumin Market Size, Share & Industry Analysis, By Product (Alburex, Octalbin, Plasbumin, and Others), By Application (Therapeutics, Diagnostics, and Research), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Industry, and Research Institutes), and Forecasts, 2025-2032

The Canada albumin market size was valued at USD 20.7 million in 2024. The market is projected to grow from USD 21.7 million in 2025 to USD 30.4 million by 2032, exhibiting a CAGR of 4.98% during the forecast period.

Human serum albumin is a plasma-derived medicinal product used for various purposes. The Canadian market is anticipated to witness a slower growth owing to the limited consumption of albumin for therapeutic purposes. Factors such as the rising burden of liver diseases, increasing usage in trauma surgeries are projected to drive overall market growth.

The market is dominated by Octapharma AG, Grifols S.A., and CSL Behring. The leading positions of these companies in the Canadian market are supported by the presence of approved products and high market penetration in the country.

MARKET DYNAMICS

MARKET DRIVERS:

Rising Burden of Liver Diseases to Propel Market Growth

The rising burden of liver diseases and cirrhosis is one of the major factors driving the Canada albumin market growth. Canadian hospitals are increasingly preferring licensed, pathogen‑reduced human albumin concentrate over unstandardized blood products in the treatment of liver cirrhosis, in turn driving the Canada albumin market demand. In addition, with the increasing number of patients progressing to complications, healthcare professionals use albumin for volume expansion and to prevent circulatory dysfunction after large-volume paracentesis or during infection management. Thus, each incremental cirrhosis case adds repeat albumin use over time, in turn propelling market expansion.

• For instance, according to the data provided by Liver Canada, the death rate from liver disease is significantly increasing in Canada.

MARKET RESTRAINTS:

High Acquisition Cost to Restrict Market Growth

Albumin is far more expensive than crystalloids, so hospitals and provincial blood programs are under constant pressure to limit its use to high-value indications. Moreover, as provincial health systems try to control spending, pharmacy & therapeutics (P&T) committees often push to curb non-essential albumin use, which restrains volume growth even if list prices are stable or rising.

• For instance, according to a study published in the National Center for Biotechnology Information (NCBI) in August 2021, albumin is imported into Canada from international suppliers at a cost of approximately 15 million USD per annum.

MARKET OPPORTUNITIES:

Rising Use in Research and Biomanufacturing Offers Significant Growth Opportunities

Rising use of albumin in research and biomanufacturing presents an important opportunity for market growth. Albumin is increasingly being used in cell-culture media and bioprocess applications, further diversifying demand. Additionally, in biomanufacturing, human serum albumin is increasingly used as a multifunctional excipient and stabilizer in complex biologics and vaccine formulations, improving stability, preventing aggregation, and preserving viral titer. Owing to this, the demand for the product is anticipated to increase in the near future, in turn offering lucrative growth opportunities.

CANADA ALBUMIN MARKET TRENDS:

Increasing Usage in Cardiac Surgery and Critical Care Is a Significant Trend Observed in Canada Albumin Market

Significant use of albumin in cardiac surgery and critical care is an emerging trend in Canada. These settings concentrate high-value, protocol-driven usage of albumin. This shows the sustained demand for the product. Additionally, initiatives by Canadian Blood Services also boost the usage of albumin in cardiac surgeries and critical care.

• For instance, a 2022 survey of Canadian cardiovascular anesthesiologists and intensivists found that about 62% use albumin for fluid resuscitation in cardiac surgical patients.

MARKET CHALLENGES:

Dependence on Imported Plasma and Global Supply Dynamics Pose a Significant Challenge for the Market

Supply chain vulnerability is one of the major challenges faced by the market. Various sources have mentioned that the majority of the plasma used to manufacture albumin for Canadian patients is collected outside Canada and that no albumin products are currently manufactured domestically. This makes Canada heavily dependent on international plasma collectors and fractionators. Furthermore, in times of global plasma shortage or manufacturing disruption, Canadian market growth also gets hampered to a certain extent.

Download Free sample to learn more about this report.

Segmentation Analysis

By Product

Wide Availability of Product to Propel Segmental Growth

Based on product, the market is divided into Alburex, Octalbin, Plasbumin, and others.

The Alburex dominated the Canada albumin market with the largest market share. The product is one of the oldest and continuously marketed products with strong formulations and clinician familiarity. Additionally, Canadian provincial hospital systems also explicitly include Alburex as a standard care option, in turn supporting segment growth.

• For instance, Alberta Health Services lists Albumin 5% (Plasbumin, Alburex) and Albumin 25% (Plasbumin, Alburex) in its blood products manual.

The Octablin segment is expected to grow at a CAGR of 6.83% during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Application

High Usage of Albumin Boosted Segmental Growth

Based on application, the market is divided into therapeutics, diagnostics, and research.

In 2024, the therapeutic applications segment captured the largest Canada albumin market share. The segment is set to hold a 66.7% share in 2025. High usage of albumin as a drug in high-acuity clinical settings is majorly driving segment growth. Additionally, supportive guidelines for regulatory authorities also support segment growth.

• For instance, Canadian Blood Services’ Clinical Guide to Transfusion – Albumin lists core therapeutic indications, such as complications of cirrhosis, as therapeutic uses of albumin.

The diagnostics segment is projected to grow at a CAGR of 4.33% during the study period.

By End User

High Patient Volume Drive the Segmental Growth of Hospitals & Clinics

Based on end user, the market is segmented into hospitals & clinics, the pharmaceutical & biotechnology industry, and research institutes.

In 2024, the hospitals & clinics segment captured the largest Canada albumin market share. The hospitals & clinics are the primary settings for the administration of albumin. This administration is managed in hospital settings, not in outpatient labs or basic research facilities, in turn supporting the dominance of the segment. The hospitals & clinics segment is set to hold a 52.5% share in 2025.

The pharmaceutical & biotechnology industry segment is projected to grow at a CAGR of 5.56% during the study period.

COMPETITIVE LANDSCAPE

Key Industry Players:

Strategic Collaborations by Key Players to Strengthen Their Market Position

The Canada albumin market is highly concentrated, reflects a procurement-driven structure. The market is dominated by CSL Behring and Octapharma AG, with collaborations for supply in Canada.

Other notable players in the market are Grifols S.A. and Baxter. These companies are focusing on winning supply agreements with regulatory authorities in the Canadian market.

LIST OF KEY CANADA ALBUMIN COMPANIES PROFILED:

• CSL Behring LLC. (U.S.)
• Octapharma AG (Switzerland)
• Grifols S.A. (Spain)
• Baxter (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• June 2023: Grifols Group signed an agreement with Canadian Plasma Resources to secure plasma supply in Canada.

REPORT COVERAGE

The Canada albumin market analysis provides a detailed study of the market size & forecast by all the market segments included in the report. The report also provides insights into market dynamics and trends expected to drive the market during the forecast period. The Canada albumin market report also comprises key aspects, such as an overview of technological advancements, product launches, insights on strategic partnerships, mergers & acquisitions, and key industry developments in Canada. The Canada albumin market forecast also provides a detailed competitive landscape, including market share and profiles of major industry players.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation